| News Updates |
 |
Once-Weekly Oral ISL/LEN Combo for HIV Treatment Found Safe and Effective, With High Adherence
Infectious Disease Special Edition | October 17, 2025
|
|
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with...
ViiV Healthcare | October 17, 2025
|
|
Novel HIV Combo Therapy of Lenacapavir and 2 bNAbs Found Effective, Well Tolerated in in Phase 2 Trial
Infectious Disease Special Edition | October 17, 2025
|
|
Integrase inhibitors maintain efficacy despite “outside” mutations, UK study finds
European AIDS Treatment Group | October 12, 2025
|
|
'We can end HIV': Groundbreaking preventative drug to be rolled out for $40 a year from 2027
France24 | September 25, 2025
|
|
Gates Foundation partners with Indian manufacturer to drive down cost of, accelerate access to groundbreaking HIV prevention tool
Gates Foundation | September 24, 2025
|
|
UNAIDS welcomes the announcement of new deals to make new HIV prevention medicines available and affordable for people in need
UNAIDS | September 24, 2025
|
|
HIV Drug Resistance Is Declining Over Time
POZ Magazine | September 24, 2025
|
|
From Bench to Breakthrough: How Curiosity Led to an Extraordinarily Effective HIV Drug
University of Utah Health | September 22, 2025
|
|
New oral antiretroviral shows potential as long-acting HIV pre-exposure prophylaxis
News Medical | August 26, 2025
|
|
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
Gilead | August 26, 2025
|
|
HIV: Monthly PrEP Drug Candidate Shows Promise
Newsweek | August 26, 2025
|
|
HIV Treatment Overview
NIH | August 20, 2025
|
|
Lenacapavir will not end the HIV epidemic in the current US political climate
The Lancet | August 2025
|
|
Innovative administration of long-acting injectables for HIV treatment enhancement at home (INVITE-HOME): implementation science...
NIH | August 5, 2025
|
|
IAS 2025: Pharmacists Steer Modern HIV Care Through Co-Infection Management
Pharmacy Times | July 29, 2025
|
|
WHO urges rollout of first long-acting HIV prevention jab
UN | July 14, 2025
|
|
Viiv Healthcare Presents New Data Demonstrating Positive Real-World Impact of Its Innovative Long-Acting Injectables for HIV at IAS 2025
ViiV | July 8, 2025
|
|
The Drug That Could Revolutionize the Fight Against H.I.V.
The New Yorker | June 24, 2025
|
|
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
Gilead | June 18, 2025
|
|
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention
Contagion Live | June 18, 2025
|
|
‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers
The Guardian | June 17, 2025
|
|
FDA Alert: Infectious Diseases Drug News Roundup
ISA | June 13, 2025
|
|
Gilead hit with FDA clinical hold for batch of HIV trials
Yahoo | June 11, 2025
|
| |
|
